# Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

> **NCT04688788** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Rigshospitalet, Denmark** · enrollment: 600 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Primary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Ocrelizumab
- **DRUG:** Fexofenadine
- **DRUG:** Paracetamol
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT04688788
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-28
- **Primary completion:** 2026-05-05
- **Final completion:** 2029-05-05
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2025-07-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04688788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04688788, "Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04688788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*